BIOLEVATE raises €30M Series A to make AI the compliance engine for research laboratories

BIOLEVATE (Paris) has raised €30 million in a Series A co-led by RAISE France and Orange Ventures, with EQT Ventures and the MSD Global Health Innovation Fund also participating. Founded in 2022 by Joël Belafa, the company has built an AI-native platform for regulatory compliance in research and pharmaceutical laboratories.

The problem BIOLEVATE is solving is structural: laboratories in regulated industries — pharmaceutical, biotech, medical device — carry an enormous documentation burden imposed by the frameworks they operate under. FDA's 21 CFR Part 11, EMA GMP guidelines, ISO 17025, and their equivalents require detailed records of every procedure, equipment qualification, and deviation from standard practice. In most labs, that documentation lives in a patchwork of shared drives, PDFs, binders, and LIMS systems that were built to record data, not to demonstrate compliance. When an audit arrives, assembling the evidence often takes weeks of manual work, with real risk that a gap in the record becomes a finding — and findings delay product approvals, manufacturing releases, and sometimes market access.

Automating the compliance layer

BIOLEVATE's approach is to treat compliance documentation as a structured data problem rather than a paper management problem. The platform ingests existing lab records, maps them to the specific requirements of the applicable regulatory framework, and surfaces gaps before an auditor reaches them. Rather than preparing a compliance binder for a point-in-time inspection, labs using the platform maintain a living compliance record that reflects current operational state.

The company now employs around 50 people — a headcount that the €30 million will extend as it scales commercial operations and builds out the AI layer further.

The investor mix

The co-leads carry different significance. RAISE France is an investment fund backed by French institutional capital, with a track record in deep-tech and regulated-sector companies where the sales cycle is long and trust is a prerequisite. Orange Ventures, the strategic arm of the telecoms group, brings a customer network and corporate credibility that matters in hospital and pharma procurement. EQT Ventures and the MSD Global Health Innovation Fund — the venture arm of the pharmaceutical company — bring direct proximity to regulated-industry buyers. The MSD fund's participation is particularly notable: it signals that a major pharmaceutical operator sees BIOLEVATE as solving a problem it recognises from its own operations, rather than merely as a speculative AI play.

Boston

The expansion target is the US market, specifically pharmaceutical and biotech research operations centred around Boston. FDA-regulated environments have distinct requirements — Part 11 electronic records, Part 820 quality system regulation, IND and NDA submission evidence — that differ from the European frameworks BIOLEVATE has trained its models on. The 18-month question is whether that regulatory specificity requires a material rebuild of the compliance engine, or whether the underlying data architecture generalises and the US expansion is primarily a commercial effort.